MUNICH, Germany--(BUSINESS WIRE)--Data from the pivotal phase III TONADO™ studies†,1 for tiotropium + olodaterol Respimat® FDC were presented for the first time today at the European Respiratory Society (ERS) International Congress 2014. The 52-week studies have involved more than 5,000 patients with COPD and have been part of the recent regulatory submissions in Europe and the US for tiotropium + olodaterol Respimat® FDC as a COPD maintenance therapy. Results showed that tiotropium + olodaterol Respimat® FDC brought even further lung function and quality of life benefits to patients than either compound alone.1 By adding to the significant benefits patients already get from tiotropium, the active ingredient of Spiriva®, the results indicated that an even greater number of patients treated with tiotropium + olodaterol Respimat® FDC may be able to return to a more independent life.1,2
Help employers find you! Check out all the jobs and post your resume.
